MNPR MONOPAR THERAPEUTICS Management Changes 8-K Filing 2025 - Management Change On February 28, 2025, Karthik Radhakrishnan left his role as Chief Financial Officer of Monopar Therapeutics, and Quan Vu was appointed to succeed him effective March 3, 2025, with a salary of $350,000 and stock options.Get access to all SEC 8-K filings of the MONOPAR THERAPEUTICS